2335 GMT - Sonic Healthcare lacks national scale in the U.S. despite investing A$2.3 billion in M&A there, and Barrenjoey says the path to growing its footprint is unclear. So, Barrenjoey explores a possible sale of the U.S. business and concludes it would be highly attractive to Sonic's bigger rivals. Assuming a sales price of 11-14x FY 2026 Ebitda, with proceeds used on a share buyback, Sonic's proforma EPS could change by -1% to +6% that year, Barrenjoey says. Sonic's return on invested capital could improve to 6.8%, from 6.5%. "While not necessarily financially compelling, the broader benefits of such a transaction include a decrease in maintenance capex into the U.S. region, and the ability to deploy future capital into higher returning regions such as Germany (via bolt-ons)," analyst Saul Hadassin says. (david.winning@wsj.com; @dwinningWSJ)
(END) Dow Jones Newswires
March 26, 2025 18:35 ET (22:35 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。